[{"id":"8f688b25-930e-42ca-9a40-fca5c6f5662a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890236","created_at":"2021-05-18T12:01:56.234Z","updated_at":"2025-02-25T15:54:04.644Z","phase":"Phase 1","brief_title":"Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study","source_id_and_acronym":"NCT04890236","lead_sponsor":"Emory University","biomarkers":" CD27","pipe":"","alterations":" ","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Kymriah (tisagenlecleucel-T) • ETP-47187"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 01/13/2022","start_date":" 01/13/2022","primary_txt":" Primary completion: 03/20/2024","primary_completion_date":" 03/20/2024","study_txt":" Completion: 09/04/2024","study_completion_date":" 09/04/2024","last_update_posted":"2025-01-20"},{"id":"4bbdcbf6-ccbf-4476-adeb-a48a0a44206f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225363","created_at":"2022-02-05T18:29:53.670Z","updated_at":"2024-07-02T16:35:01.290Z","phase":"Phase 1","brief_title":"Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05225363","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TAG72-CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 05/05/2022","start_date":" 05/05/2022","primary_txt":" Primary completion: 04/05/2026","primary_completion_date":" 04/05/2026","study_txt":" Completion: 04/05/2027","study_completion_date":" 04/05/2027","last_update_posted":"2024-05-23"},{"id":"310e9d9a-b69c-4442-97f5-d4d4ad2729a2","acronym":"NCI-2018-00918","url":"https://clinicaltrials.gov/study/NCT03449108","created_at":"2022-07-22T15:57:20.497Z","updated_at":"2024-07-02T16:35:02.803Z","phase":"Phase 2","brief_title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","source_id_and_acronym":"NCT03449108 - NCI-2018-00918","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • CD8 • CD28 • CD27","pipe":" | ","alterations":" CD8 expression • CD28 expression","tags":["HER-2 • CD8 • CD28 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/27/2018","start_date":" 04/27/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-17"},{"id":"f003bb6c-5459-49c1-947d-35ec28b1d2c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04135079","created_at":"2024-02-23T15:25:03.657Z","updated_at":"2024-07-02T16:35:04.833Z","phase":"","brief_title":"Immune Profiling in Multiple Myeloma","source_id_and_acronym":"NCT04135079","lead_sponsor":"Mario Boccadoro","biomarkers":" PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 04/28/2021","primary_completion_date":" 04/28/2021","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-08"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"90515a21-3e57-41de-96be-20611fb49d4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065554","created_at":"2021-10-04T12:52:56.869Z","updated_at":"2025-02-25T15:00:05.879Z","phase":"Phase 2","brief_title":"ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy","source_id_and_acronym":"NCT05065554","lead_sponsor":"Shayna Sarosiek, MD","biomarkers":" CD20 • CD22 • IL2RA • CD5 • SDC1 • CD27 • MME • ITGAE • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD22 • IL2RA • CD5 • SDC1 • CD27 • MME • ITGAE • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-04-17"},{"id":"7158f3c8-048e-44f4-84c4-9fea0fbb9783","acronym":"","url":"https://clinicaltrials.gov/study/NCT06282978","created_at":"2024-02-29T03:33:45.743Z","updated_at":"2024-07-02T16:35:16.129Z","phase":"Phase 2","brief_title":"Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes","source_id_and_acronym":"NCT06282978","lead_sponsor":"PETHEMA Foundation","biomarkers":" KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81","pipe":" | ","alterations":" CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression","tags":["KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elrexfio (elranatamab-bcmm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/23/2023","start_date":" 11/23/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-03-06"},{"id":"f7ccd756-4413-4530-bc65-1188b9dc3cbc","acronym":"DIAL","url":"https://clinicaltrials.gov/study/NCT03038672","created_at":"2021-01-18T14:57:44.271Z","updated_at":"2024-07-02T16:35:20.479Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas","source_id_and_acronym":"NCT03038672 - DIAL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • TMB • BCL2 • BCL6 • CD27 • IRF4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD27 expression","tags":["ALK • TMB • BCL2 • BCL6 • CD27 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD27 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • varlilumab (CDX 1127) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 05/26/2023","primary_completion_date":" 05/26/2023","study_txt":" Completion: 10/25/2024","study_completion_date":" 10/25/2024","last_update_posted":"2024-02-07"},{"id":"f9e8a0b7-2582-42c3-ba42-3a60ab5f129f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323202","created_at":"2024-01-18T18:18:19.652Z","updated_at":"2024-07-02T16:35:23.036Z","phase":"Phase 1","brief_title":"Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H\u0026N","source_id_and_acronym":"NCT04323202","lead_sponsor":"Brian Gastman","biomarkers":" CD8 • PD-1 • LAG3 • IL2RA • TIGIT • CD4 • FASLG • CD27 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["CD8 • PD-1 • LAG3 • IL2RA • TIGIT • CD4 • FASLG • CD27 • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-01-18"},{"id":"08feeadb-5307-4d34-8d6c-05bf33aa5481","acronym":"","url":"https://clinicaltrials.gov/study/NCT02978118","created_at":"2021-01-18T14:38:33.926Z","updated_at":"2024-07-02T16:35:25.713Z","phase":"","brief_title":"Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)","source_id_and_acronym":"NCT02978118","lead_sponsor":"Duke University","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • CD27","pipe":" | ","alterations":" TILs","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2023-12-20"},{"id":"5ee1ae6e-0047-4793-9812-f63a9637ae81","acronym":"","url":"https://clinicaltrials.gov/study/NCT03089606","created_at":"2021-01-18T15:13:27.812Z","updated_at":"2025-02-25T16:05:57.894Z","phase":"Phase 2","brief_title":"Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker","source_id_and_acronym":"NCT03089606","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" LAG3 • HAVCR2 • CD27","pipe":" | ","alterations":" IDO1 expression","tags":["LAG3 • HAVCR2 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 04/19/2017","start_date":" 04/19/2017","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2023-11-15"},{"id":"15408d6a-1840-4968-924b-1d11cb2d1ea9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03680521","created_at":"2021-05-19T21:56:08.066Z","updated_at":"2024-07-02T16:35:34.782Z","phase":"Phase 2","brief_title":"Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT03680521","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" PD-L1 • CD8 • PD-1 • CD4 • CD27","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • PD-1 • CD4 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sitravatinib (MGCD516)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 04/27/2020","primary_completion_date":" 04/27/2020","study_txt":" Completion: 05/18/2023","study_completion_date":" 05/18/2023","last_update_posted":"2023-10-04"},{"id":"ded56621-91d5-4fd3-83a0-0e173411e008","acronym":"","url":"https://clinicaltrials.gov/study/NCT05519397","created_at":"2022-08-29T13:03:09.156Z","updated_at":"2024-07-02T16:35:37.582Z","phase":"","brief_title":"Evaluation of the Role of Immune Checkpoints in Response to Breast Cancer Neoadjuvant Therapy","source_id_and_acronym":"NCT05519397","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • PD-L2 • HAVCR2 • IL2RA • CD27 • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • PD-L2 • HAVCR2 • IL2RA • CD27 • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2023-09-11"},{"id":"1eb4bfe6-a419-4cd5-9ec6-57d058690b45","acronym":"","url":"https://clinicaltrials.gov/study/NCT01813539","created_at":"2021-01-18T08:03:00.872Z","updated_at":"2024-07-02T16:35:40.457Z","phase":"Phase 1/2","brief_title":"A Study of ARGX-110 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT01813539","lead_sponsor":"OncoVerity, Inc.","biomarkers":" CD70 • CD27","pipe":"","alterations":" ","tags":["CD70 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cusatuzumab (ARGX-110)"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 02/27/2013","start_date":" 02/27/2013","primary_txt":" Primary completion: 07/10/2020","primary_completion_date":" 07/10/2020","study_txt":" Completion: 07/10/2020","study_completion_date":" 07/10/2020","last_update_posted":"2023-08-09"},{"id":"b7b91d43-2908-4714-880d-0a8d2ca7e7e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03030612","created_at":"2021-01-18T14:55:03.502Z","updated_at":"2024-07-02T16:35:40.566Z","phase":"Phase 1/2","brief_title":"A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)","source_id_and_acronym":"NCT03030612","lead_sponsor":"OncoVerity, Inc.","biomarkers":" CD27","pipe":"","alterations":" ","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • cusatuzumab (ARGX-110)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2023-08-09"},{"id":"976ac03b-ec3e-471c-b247-2d7d7e9d91d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04081688","created_at":"2021-01-18T19:59:05.021Z","updated_at":"2024-07-02T16:35:42.115Z","phase":"Phase 1","brief_title":"Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC","source_id_and_acronym":"NCT04081688","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" BRAF • ALK • ROS1 • LAG3 • IDO1 • CD27","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement","tags":["BRAF • ALK • ROS1 • LAG3 • IDO1 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • varlilumab (CDX 1127)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 09/11/2019","start_date":" 09/11/2019","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-07-25"},{"id":"4cac8cfd-eacc-4f31-936f-dfb51beed513","acronym":"P30CA023074","url":"https://clinicaltrials.gov/study/NCT03422536","created_at":"2021-01-18T16:53:06.344Z","updated_at":"2024-07-02T16:35:42.620Z","phase":"Phase 2","brief_title":"Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT03422536 - P30CA023074","lead_sponsor":"University of Arizona","biomarkers":" CD27","pipe":" | ","alterations":" EGFR mutation • PIK3CA mutation","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • ficlatuzumab (AV-299)"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 12/05/2017","start_date":" 12/05/2017","primary_txt":" Primary completion: 03/29/2022","primary_completion_date":" 03/29/2022","study_txt":" Completion: 04/05/2022","study_completion_date":" 04/05/2022","last_update_posted":"2023-07-19"},{"id":"36ca1f5c-c2f6-4841-9b20-252eb2f23150","acronym":"","url":"https://clinicaltrials.gov/study/NCT04987996","created_at":"2021-08-03T18:52:59.526Z","updated_at":"2024-07-02T16:35:46.330Z","phase":"Phase 2","brief_title":"GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients","source_id_and_acronym":"NCT04987996","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" CD8 • IL2RA • CCR7 • CD27 • LGALS3 • FAS • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["CD8 • IL2RA • CCR7 • CD27 • LGALS3 • FAS • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • belapectin (GR-MD-02)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2023-06-06"},{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"3f1dc61e-e2f1-443c-8183-3acd9f434fbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03369301","created_at":"2021-01-18T16:37:46.259Z","updated_at":"2024-07-02T16:36:16.277Z","phase":"","brief_title":"The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency","source_id_and_acronym":"NCT03369301","lead_sponsor":"Octapharma","biomarkers":" CD8 • CD4 • NCAM1 • CD14 • CD27","pipe":"","alterations":" ","tags":["CD8 • CD4 • NCAM1 • CD14 • CD27"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 09/25/2017","start_date":" 09/25/2017","primary_txt":" Primary completion: 11/22/2019","primary_completion_date":" 11/22/2019","study_txt":" Completion: 11/22/2019","study_completion_date":" 11/22/2019","last_update_posted":"2022-03-02"},{"id":"97f80bfd-cb17-4afb-a460-edf78759b52c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05095103","created_at":"2021-10-27T15:53:19.131Z","updated_at":"2024-07-02T16:36:22.385Z","phase":"","brief_title":"Immune Profiles in Myasthenia Gravis","source_id_and_acronym":"NCT05095103","lead_sponsor":"University of Manchester","biomarkers":" CD27","pipe":"","alterations":" ","tags":["CD27"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 163","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2021-10-27"},{"id":"b6de17b5-794f-440f-a5e5-f1a349e84075","acronym":"RUE-DDGP","url":"https://clinicaltrials.gov/study/NCT04999878","created_at":"2021-08-11T14:55:25.152Z","updated_at":"2024-07-02T16:36:26.648Z","phase":"Phase 4","brief_title":"A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.","source_id_and_acronym":"NCT04999878 - RUE-DDGP","lead_sponsor":"Zhengzhou University","biomarkers":" IL2 • CD27 • XIAP • PRF1 • UNC13D • ISG20 • RAB27A • STXBP2","pipe":"","alterations":" ","tags":["IL2 • CD27 • XIAP • PRF1 • UNC13D • ISG20 • RAB27A • STXBP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Jakafi (ruxolitinib) • etoposide IV • dexamethasone • Oncaspar liquid (pegaspargase)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/30/2021","start_date":" 05/30/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2021-08-11"},{"id":"cca55acd-fe7d-4fd1-a867-4d67afcb638c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02179515","created_at":"2021-01-18T10:09:59.893Z","updated_at":"2024-07-02T16:36:35.567Z","phase":"Phase 1","brief_title":"Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)","source_id_and_acronym":"NCT02179515","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • IFNG • TNFA • IL2 • ICAM1 • IL10 • CD27 • LAMP1 • CD58 • CD40LG • IL4","pipe":" | ","alterations":" ER positive • EGFR mutation • CD8 expression","tags":["CD8 • IFNG • TNFA • IL2 • ICAM1 • IL10 • CD27 • LAMP1 • CD58 • CD40LG • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR mutation • CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BN-Brachyury"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 06/28/2014","start_date":" 06/28/2014","primary_txt":" Primary completion: 04/06/2017","primary_completion_date":" 04/06/2017","study_txt":" Completion: 02/28/2018","study_completion_date":" 02/28/2018","last_update_posted":"2021-01-26"},{"id":"6ffd26d0-764c-4b8b-a3bb-a291e30726d2","acronym":"ZENITH","url":"https://clinicaltrials.gov/study/NCT03159845","created_at":"2021-01-18T15:34:43.301Z","updated_at":"2024-07-02T16:36:51.816Z","phase":"Phase 2","brief_title":"Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies","source_id_and_acronym":"NCT03159845 - ZENITH","lead_sponsor":"Azienda Ospedaliero, Universitaria Pisana","biomarkers":" CD8 • CD28 • CD27","pipe":"","alterations":" ","tags":["CD8 • CD28 • CD27"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 09/10/2019","primary_completion_date":" 09/10/2019","study_txt":" Completion: 09/10/2019","study_completion_date":" 09/10/2019","last_update_posted":"2020-01-07"}]